Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2012 August;53(4) > The Journal of Cardiovascular Surgery 2012 August;53(4):447-57

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,179


eTOC

 

  INNOVATIVE TECHNOLOGIES FOR SUPERFICIAL FEMORAL ARTERY (SFA) OCCLUSIONS


The Journal of Cardiovascular Surgery 2012 August;53(4):447-57

Copyright © 2012 EDIZIONI MINERVA MEDICA

lingua: Inglese

The role of superficial femoral artery endoluminal bypass in long de novo lesions and in-stent restenosis

Doomernik D. E., Golchehr B., Lensvelt M. M. A., Reijnen M. M. P. J.

Department of Surgery, Rijnstate Hospital, Arnhem, The Netherlands


PDF  


AIM: Results of endovascular treatment for long de novo lesions of the superficial femoral artery (SFA) are limited by in-stent restenosis (ISR). Polytetrafluoroethylene (PTFE) covered stents are developed to reduce the incidence of ISR. This study was conducted to summarize available data on the use of endoprosthesis in the treatment of SFA occlusive disease and to evaluate their use in the treatment of ISR.
METHODS: A systematic literature search was performed, using MEDLINE, EMBASE and Cochrane databases. Reports on the application of Hemobahn® and Viabahn® endoprosthesis in the treatment of long de-novo lesions and ISR of the SFA were included.
RESULTS: A total of 19 articles were included. Technical success rates varied between 95-100%. Case series have shown 1-year primary patency rates varying between 44% and 86%, with secondary patency rates between 58% and 93%. Large differences in patient and lesion characteristics, medical therapy and developments in stent-graft design complicate comparisons between studies. Randomized studies have shown a superiority of the endoprosthesis above angioplasty only and similar patency rates with above-knee prosthetic femoro-popliteal bypass up to 48 months. Data on the use of endografts for ISR are scarce.
CONCLUSION: The use of an endoprosthesis for SFA occlusive disease is an effective and safe treatment strategy for long de novo lesions. Patient selection and adequate medical support appear to be important in achieving long term patency. Data focusing on the effectiveness of endoprosthesis for ISR are still limited.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

mmpj.reijnen@gmail.com